Kang Nyeong Lee, Oh Young Lee, Hoon Jai Chun, Jin Il Kim, Sung Kook Kim, Sang Woo Lee, Kyung Sik Park, Kook Lae Lee, Suck Chei Choi, Jae-Young Jang, Gwang Ha Kim, In-Kyung Sung, Moo In Park, Joong Goo Kwon, Nayoung Kim, Jae Jun Kim, Soo Teik Lee, Hyun Soo Kim, Ki Bae Kim, Yong Chan Lee, Myung-Gyu Choi, Joon Seong Lee, Hwoon-Yong Jung, Kwang Jae Lee, Jie-Hyun Kim, Hyunsoo Chung
BACKGROUND: Fexuprazan, a novel potassium-competitive acid blocker, reversibly suppresses the K+ /H+ -ATPase enzyme in proton pumps within gastric parietal cells. Fexuprazan's suppression of gastric acid was maintained in healthy individuals for 24 h in a dose-dependent manner. AIM: To compare fexuprazan to esomeprazole and establish its efficacy and safety in patients with erosive esophagitis (EE). METHODS: Korean adult patients with endoscopically confirmed EE were randomized 1:1 to receive fexuprazan 40 mg or esomeprazole 40 mg once daily for eight weeks...
November 28, 2022: World Journal of Gastroenterology: WJG